Core Insights - The ongoing centralized procurement of low-value medical consumables, such as indwelling needles and foam dressings, aims to enhance market penetration and domestic production rates, allowing domestic companies to gain a larger market share through innovation and cost control [1][2] Group 1: Procurement Mechanism - The procurement method for indwelling needles is based on "volume-linked" pricing, which considers the purchasing entity's usage needs and market price levels to determine selected products and procurement volumes [1] - The centralized procurement mechanism aims to standardize the quality and pricing of low-value medical consumables, addressing issues of quality inconsistency and price disparities in the market [2][7] Group 2: Economic Impact - The centralized procurement has significantly reduced costs for patients and medical institutions, with examples showing that the cost of hip joint replacement surgery dropped from approximately 80,000 yuan to 30,000 yuan post-procurement [3] - The implementation of centralized procurement has led to increased surgical volumes in hospitals, with one hospital reporting an increase from 4,500 to 6,700 surgeries annually, resulting in a 12% increase in physician income [3] Group 3: Market Dynamics - The market is witnessing a shift in commercial rules, with reduced profit margins for manufacturers and the exit of many intermediaries, prompting companies to adopt stricter cost control and efficiency measures [5] - The competitive landscape is evolving, with foreign companies actively participating in the market and leveraging centralized procurement as an opportunity for innovation and market expansion [6][7] Group 4: Innovation and Development - Companies are expected to increase R&D investments to introduce new products and technologies that meet market and clinical demands, with a focus on diversifying and differentiating their offerings [6] - The export of low-value medical consumables is on the rise, contributing to the long-term stable development of the industry, with leading companies like Weigao Group and Blue Sail Medical leveraging scale, innovation, and brand advantages [6]

从市场发展趋势和临床需求来看， 具有多功能、新材质、高附加值的高端医用敷料正逐渐成为市场和临床的"新宠"，其需求日益迫切。 与此同时，国家也建议优先选用屏障性敷料，这一政策导向为中国伤口护理市场的高端化发展注入了强劲动力。 业内预计，未来三年内高端产品的市场渗透率将从当 前约20%的市占率快速 提升至40% ，高端医用敷料产业正迎来前所未有的发展机遇 。 在人口老龄化进程及国民健康意识提升的双重驱动下，中国综合医院手术量不断攀升，2019年全国手术量突破5900万台次，按照每台手术术后平均使用15-20片敷 料计算， 催生10亿片/年左右的医用敷料刚需市场，相当于每天超275万片临床消耗！ 此外， 门诊换药和慢性伤口护理等创面治疗管理需求 也逐年增多，2023年中国医用敷料市场规模约为 123.71亿元 ，同比 增长13.64% 。 # 需求与痛点共振｜切入高端医用敷料市场，正当时！ 然而，现阶段纱布、无纺布等传统医用敷料仍占主导地位，其市场份额 超过80% 。尽管水胶体敷料、银离子敷料、藻酸钙盐敷料等新型敷料近年来逐渐崭露头角， 但在临床应用中，仍有许多复杂问题难以解决。因此，临床实践在医用敷料的选择和使用 ...

随着人口老龄化问题的加剧，长期卧床的老年患者、残障患者及重病患者数量增多，导致褥疮的发生率上升。褥疮不仅是一个公共健康 问题，也给医疗系统和患者带来了巨大的负担。因此，治疗褥疮的药物和敷料需求持续增长。 产品种类丰富 目前治疗褥疮的药物主要分为两大类：敷料类和抗生素类药膏。敷料类产品包括水胶体敷料、泡沫敷料、银离子敷料等，主要用于创面 保护和促进愈合；抗生素药膏如莫匹罗星软膏、红霉素软膏等，用于防治创面感染。随着科技进步，越来越多的新型敷料（如生物可降 解敷料）和具有抗菌、促进愈合作用的药物投入市场，治疗效果不断提升。 褥疮类药物是指用于预防、治疗和管理因长时间压力导致的皮肤及皮下组织损伤（即褥疮或压疮）的一类药物和护理产品。这些药物和 产品旨在减轻疼痛、控制感染、促进伤口愈合，并尽量减少并发症的发生。本报告统计范围包括患者中最常用的褥疮敷料和抗生素药 膏。 褥疮类药物行业目前现状分析 市场需求增长 技术创新推动行业发展 新技术和新材料的应用，尤其是水凝胶、泡沫敷料和银离子敷料等高科技产品，使得治疗褥疮的效果更加显著。这些产品具有更好的吸 湿性、抗菌性和创面保护性，改善了患者的使用体验和治疗效果。同时，生物医 ...